Trial Profile

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rindopepimut (Primary) ; Keyhole limpet haemocyanin; Sargramostim; Temozolomide
Indications Glioblastoma; Gliosarcoma
Focus Registrational; Therapeutic Use
Acronyms ACT-IV
Sponsors Celldex Therapeutics Inc

Most Recent Events

06 Apr 2022 This trial has been completed in Netherland (End Date: 15 Apr 2016), according to European Clinical Trials Database record.
22 Aug 2017 Primary endpoint (Overall Survival) has not been met as per the results published in the Lancet Oncology
22 Aug 2017 Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com